Braveheart Bio, Inc. BRVE
20.98 USD +1.36 (+6.93%)
Nov 11, 2026, 12:24 PM EST
19.41 Day range 21.85
16.70 52-week range 32.00
- YTD
- -29.60%
- 1 year
- -29.60%
News
globenewswire.com Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen…
globenewswire.com Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
seekingalpha.com Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
marketbeat.com Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial Braveheart Bio NASDAQ: BRVE presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances the treatment through…
benzinga.com Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52…
globenewswire.com Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks
benzinga.com Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar Oral Abstract PresentationTitle: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in…- benzinga.com Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.
- benzinga.com Braveheart Bio Q2 EPS $(2.51) Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of…
benzinga.com This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48 Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.
benzinga.com This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…- benzinga.com Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40 Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Overweight rating and announces Price Target of $40.
benzinga.com Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45 Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $45.